View in EDS

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Authors: Costa LJ; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL., Davies FE; Myeloma Research Program, Perlmutter Cancer Center, NYU Langone, New York, NY., Monohan GP; Division of Hematology and Blood & Marrow Transplant, University of Kentucky, Lexington, KY., Kovacsovics T; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT., Burwick N; Division of Hematology, University of Washington, Seattle, WA., Jakubowiak A; Myeloma Program, The University of Chicago Medicine, Chicago, IL., Kaufman JL; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Hong WJ; Genentech, Inc, South San Francisco, CA., Dail M; Genentech, Inc, South San Francisco, CA., Salem AH; AbbVie, Inc, North Chicago, IL.; Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt., Yang X; AbbVie, Inc, North Chicago, IL., Masud AA; AbbVie, Inc, North Chicago, IL., Munasinghe W; AbbVie, Inc, North Chicago, IL., Ross JA; AbbVie, Inc, North Chicago, IL., Bueno OF; AbbVie, Inc, North Chicago, IL., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN; and., Stadtmauer EA; Division of Hematology and Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA.
Source: Blood advances [Blood Adv] 2021 Oct 12; Vol. 5 (19), pp. 3748-3759.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34470049
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Costa+LJ%22">Costa LJ</searchLink>; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL.<br /><searchLink fieldCode="AU" term="%22Davies+FE%22">Davies FE</searchLink>; Myeloma Research Program, Perlmutter Cancer Center, NYU Langone, New York, NY.<br /><searchLink fieldCode="AU" term="%22Monohan+GP%22">Monohan GP</searchLink>; Division of Hematology and Blood & Marrow Transplant, University of Kentucky, Lexington, KY.<br /><searchLink fieldCode="AU" term="%22Kovacsovics+T%22">Kovacsovics T</searchLink>; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT.<br /><searchLink fieldCode="AU" term="%22Burwick+N%22">Burwick N</searchLink>; Division of Hematology, University of Washington, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Jakubowiak+A%22">Jakubowiak A</searchLink>; Myeloma Program, The University of Chicago Medicine, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Kaufman+JL%22">Kaufman JL</searchLink>; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.<br /><searchLink fieldCode="AU" term="%22Hong+WJ%22">Hong WJ</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Dail+M%22">Dail M</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Salem+AH%22">Salem AH</searchLink>; AbbVie, Inc, North Chicago, IL.; Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt.<br /><searchLink fieldCode="AU" term="%22Yang+X%22">Yang X</searchLink>; AbbVie, Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Masud+AA%22">Masud AA</searchLink>; AbbVie, Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Munasinghe+W%22">Munasinghe W</searchLink>; AbbVie, Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Ross+JA%22">Ross JA</searchLink>; AbbVie, Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Bueno+OF%22">Bueno OF</searchLink>; AbbVie, Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Kumar+SK%22">Kumar SK</searchLink>; Division of Hematology, Mayo Clinic, Rochester, MN; and.<br /><searchLink fieldCode="AU" term="%22Stadtmauer+EA%22">Stadtmauer EA</searchLink>; Division of Hematology and Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2021 Oct 12; Vol. 5 (19), pp. 3748-3759.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34470049
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2020004146
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3748
    Titles:
      – TitleFull: Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Costa LJ
      – PersonEntity:
          Name:
            NameFull: Davies FE
      – PersonEntity:
          Name:
            NameFull: Monohan GP
      – PersonEntity:
          Name:
            NameFull: Kovacsovics T
      – PersonEntity:
          Name:
            NameFull: Burwick N
      – PersonEntity:
          Name:
            NameFull: Jakubowiak A
      – PersonEntity:
          Name:
            NameFull: Kaufman JL
      – PersonEntity:
          Name:
            NameFull: Hong WJ
      – PersonEntity:
          Name:
            NameFull: Dail M
      – PersonEntity:
          Name:
            NameFull: Salem AH
      – PersonEntity:
          Name:
            NameFull: Yang X
      – PersonEntity:
          Name:
            NameFull: Masud AA
      – PersonEntity:
          Name:
            NameFull: Munasinghe W
      – PersonEntity:
          Name:
            NameFull: Ross JA
      – PersonEntity:
          Name:
            NameFull: Bueno OF
      – PersonEntity:
          Name:
            NameFull: Kumar SK
      – PersonEntity:
          Name:
            NameFull: Stadtmauer EA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 10
              Text: 2021 Oct 12
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 19
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1